Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Development of PSMA-Targeted Liposomal Zinc for Prostate Cancer Therapy.

Nanomaterials (Basel, Switzerland)·2026
Same author

The Multifaceted Role of microRNA-10b (miR-10b) in Glioblastoma: From Oncogenic Driver to Therapeutic Target.

Cells·2026
Same author

Nanotherapy Targeting miR-10b Improves Survival in Orthotopic Glioblastoma Models.

Journal of functional biomaterials·2026
Same author

Image-guided In Vivo Tracking of Transplanted Distal Lung Epithelial Progenitor Cells for Pulmonary Fibrosis Using Magnetic Particle Imaging.

Journal of visualized experiments : JoVE·2025
Same author

miR-10b as a Clinical Marker and a Therapeutic Target for Metastatic Breast Cancer.

Technology in cancer research & treatment·2025
Same author

Wearable Surface Electromyography System to Predict Freeze of Gait in Parkinson's Disease Patients.

Sensors (Basel, Switzerland)·2024
Same journal

Direct Androgen Receptor Antagonism Enhances Therapeutic PSMA Radioligand Uptake in Prostate Cancer Models.

Molecular imaging and biology·2026
Same journal

Advances in PD-L1 Targeted Molecular Imaging Radiotracers Research: From Preclinical Exploration to Clinical Application.

Molecular imaging and biology·2026
Same journal

Preclinical Evaluation of [<sup>18</sup>F]JNJ-1: A Novel Positron Emission Tomography Ligand Targeting AMPAR/TARP γ8.

Molecular imaging and biology·2026
Same journal

Probing Early Myocardial Remodeling in Response to a High-Fat Diet in Mice by Evaluation of Extracellular Volume Fraction Using 4D Retrospectively Gated Micro-CT Imaging.

Molecular imaging and biology·2026
Same journal

Molecular Imaging of Butyrylcholinesterase Associated with Amyloid-β Plaques Distinguishes 5XFAD from Wild-Type Mice: A Proof-of-Concept.

Molecular imaging and biology·2026
Same journal

Brain Amyloid Deposition Is Negatively Associated with Cardiac Amyloid Retention in Apo E4 Carriers: A Pilot Study.

Molecular imaging and biology·2026
See all related articles

Related Experiment Video

Updated: Jun 15, 2026

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo
12:42

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo

Published on: January 7, 2019

Template-Directed RIG-I Agonist Assembly for Image-guided Targeted Cancer Immunotherapy.

Subrata K Ghosh1, Douglas Lazarus2, Neil Robertson1

  • 1TransCode Therapeutics, Inc., 400 Trade Center, Suite 5900, Woburn, MA, 01801, USA.

Molecular Imaging and Biology
|February 19, 2026
PubMed
Summary
This summary is machine-generated.

This study developed a novel nanoparticle delivery system for a RIG-I agonist, enabling targeted tumor cell apoptosis and immune response induction. This strategy shows promise for image-guided cancer immunotherapy.

Keywords:
Image-guided therapyImmunotherapyOligonucleotide deliveryRIG-I signaling

More Related Videos

Pretargeted Radioimmunotherapy Based on the Inverse Electron Demand Diels-Alder Reaction
09:44

Pretargeted Radioimmunotherapy Based on the Inverse Electron Demand Diels-Alder Reaction

Published on: January 29, 2019

A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy
09:56

A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy

Published on: February 21, 2025

Related Experiment Videos

Last Updated: Jun 15, 2026

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo
12:42

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo

Published on: January 7, 2019

Pretargeted Radioimmunotherapy Based on the Inverse Electron Demand Diels-Alder Reaction
09:44

Pretargeted Radioimmunotherapy Based on the Inverse Electron Demand Diels-Alder Reaction

Published on: January 29, 2019

A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy
09:56

A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy

Published on: February 21, 2025

Area of Science:

  • Oncology
  • Immunology
  • Nanotechnology
  • Molecular Biology

Background:

  • Tumor-specific immunotherapies offer targeted cancer treatment with reduced toxicity.
  • Pattern recognition receptors like RIG-I can induce antitumor responses but face delivery and off-target challenges.
  • Current limitations hinder the clinical translation of RIG-I-based immunotherapies.

Purpose of the Study:

  • To develop a strategy for intracellular assembly of a RIG-I agonist on a tumor-specific RNA template.
  • To overcome delivery issues and off-target effects of RIG-I agonists for cancer treatment.
  • To utilize a superparamagnetic nanoparticle carrier for targeted delivery and image-guided therapy.

Main Methods:

  • Conjugation of a single-stranded anti-miR-21 5'-triphosphate RIG-I agonist to dextran-coated nanoparticles (TTX).
  • In vitro and in vivo testing in a B16-F10 melanoma mouse model.
  • Magnetic resonance imaging (MRI) for visualizing nanoparticle delivery and therapeutic efficacy assessment.

Main Results:

  • Demonstrated miRNA-21-dependent RIG-I signaling and apoptosis in melanoma cells.
  • Inhibited tumor growth and induced immunity against tumor rechallenge in an animal model.
  • Confirmed the ability of the nanoparticle system to initiate specific RIG-I signaling.

Conclusions:

  • The template-driven approach facilitates RIG-I activation within tumor cells.
  • Systemic delivery of RIG-I agonists via nanoparticles enhances antitumor immune responses.
  • This strategy advances RIG-I as a clinically relevant target in oncology.